How POTS treatment is built, in order: non-drug measures, then medicines matched to your symptoms, with the guideline ratings and the honest limits of the evidence.
Treatment for POTS starts with measures you can begin today and adds medicines when symptoms stay disruptive. The 2015 Heart Rhythm Society statement and a 2026 JAMA review both put non-drug treatment first and describe drug therapy as individualized, with limited evidence.
Clinicians borrow drugs approved for other conditions and match them to the dominant problem: a beta-blocker or ivabradine for a fast rate, midodrine to tighten blood vessels, fludrocortisone to expand volume, pyridostigmine when beta-blockers fit poorly. The medications guide and the treatment evidence page show the trial behind each.
21 RANDOMIZED TRIALS, 750 PATIENTS IN ALL
One square per trial. They average about 36 patients each.
RESPONSE RATES ACROSS 28 STUDIES
The authors called the evidence base extremely limited.
Weak to moderate. A 2026 consensus statement of international experts also argues that treatment needs to cover patients who fall just under the heart rate threshold.
This page informs and does not diagnose. Only a clinician who can examine you and see your whole history can interpret your numbers.
Want a record to bring to your visit? The POTS app guides the stand test at home and graphs your heart rate. See the app